FDA Approves Tucatinib as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer
The oral HER2 inhibitor, added to trastuzumab and pertuzumab after induction, extended median progression-free survival by 8.6 months in HER2CLIMB-05. The label carries a boxed warning for hepatotoxicity.
Tucatinib has moved up in the treatment sequence for HER2-positive metastatic breast cancer. On Oct. 7, the Food and Drug Administration approved tucatinib (Tukysa, Seagen, a Pfizer subsidiary) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
The drug was first approved in April 2020 with trastuzumab and capecitabine for patients who had received one or more prior anti-HER2 regimens in the metastatic setting. The new indication brings it into the first-line setting, as an addition to the antibody pair that patients continue after induction chemotherapy.
What HER2CLIMB-05 showed
According to the FDA, efficacy was evaluated in 654 adults in HER2CLIMB-05, a randomized, double-blind, placebo-controlled trial. Eligible patients had no evidence of disease progression by investigator assessment after 4 to 8 cycles of induction with trastuzumab, pertuzumab and a taxane, and could have brain metastases. They received tucatinib 300 mg or placebo orally twice daily with trastuzumab and pertuzumab, given intravenously or as the subcutaneous fixed-dose combination with hyaluronidase. Patients with hormone receptor-positive disease were permitted to continue endocrine therapy.
Median investigator-assessed progression-free survival was 24.9 months in the tucatinib arm and 16.3 months in the placebo arm, with a hazard ratio of 0.64 (95% CI, 0.51 to 0.80). Overall survival data were not mature at the time of the analysis, the FDA said.
The 8.6-month difference reflects what tucatinib adds to dual antibody maintenance. Whether it translates into longer survival is not yet known.
"The HER2CLIMB-05 findings support TUKYSA plus trastuzumab and pertuzumab as a chemotherapy-free maintenance strategy that allows us to target HER2-positive tumors from multiple angles and can help prolong disease control," said Erika Hamilton, M.D., the trial's principal investigator and director of breast cancer research at Sarah Cannon Research Institute, in Pfizer's announcement, as quoted by Pharmaceutical Executive. The results were presented at the 2025 San Antonio Breast Cancer Symposium and published in the Journal of Clinical Oncology.
The liver signal
The prescribing information carries a boxed warning for hepatotoxicity, along with warnings and precautions for diarrhea, embryo-fetal toxicity and increased serum creatinine without an effect on renal function. Pharmaceutical Executive reported that, according to Pfizer, serious hepatotoxicity occurred in 3.9 percent of patients, including one fatal case of drug-induced liver injury, and that hepatotoxicity led to discontinuation in 8 percent. The label calls for liver function testing before and during treatment.
In the published analysis, the most common treatment-emergent adverse events in the tucatinib arm were diarrhea, nausea and elevated ALT and AST, and 13.5 percent of patients discontinued tucatinib because of adverse events, Targeted Oncology reported.
Why it matters
For oncology practices, the approval adds an oral agent to a maintenance phase that has been built around two infused or injected antibodies. That brings the label's liver function testing and its warnings on diarrhea into the maintenance phase of care. It also arrives less than a year after the FDA approved trastuzumab deruxtecan with pertuzumab as a first-line option on Dec. 15, 2025, Targeted Oncology noted.
The FDA said full prescribing information will be posted on Drugs@FDA.
Priya Natarajan has run operations for multispecialty groups and writes The Script Pad's practice management column.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
